CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
-
Venezuela's Machado vows to make Nobel Peace Prize ceremony
-
Kidnapping fears strain family bonds in Nigeria
-
'Chosen' Mbappe on way to making Real Madrid history like Ronaldo: Alonso
-
Russian strikes on Ukraine trigger heating, water cuts
-
Mediators Qatar, Egypt call for next steps in Gaza truce
-
Olympic favourite Malinin pulls off stunning GP Final win
-
Venezuela's Machado to receive peace prize in Oslo: Nobel Institute
-
Russell tops practice times to outpace title-chasing trio
-
India bowl out South Africa for 270 after De Kock ton
-
England staring down the barrel under Gabba lights as Australia dominate
-
Egyptian actor faces challenge in iconic role of singer Umm Kulthum
-
Chock and Bates win Grand Prix Final ice dance
-
Starvation fears as flood toll passes 900 in Indonesia
-
Four civilians, soldier killed in Afghan-Pakistan border clash
-
Milan-Cortina chief admits venue time pinch as Olympic torch relay begins
-
England make quick start after Australia take big lead at Gabba
-
Finally! India break toss jinx as Rahul gets lucky
-
Will EU give ground on 2035 combustion-engine ban?
-
England nemesis Starc stretches Australia lead in Gabba Ashes Test
-
Banana skin 'double whammy' derails McIlroy at Australian Open
-
Epic Greaves double ton earns West Indies draw in first NZ Test
-
Thunder roll to 14th straight NBA win, Celtics beat depleted Lakers
-
Myanmar citizens head to early polls in Bangkok
-
Starvation fears as more heavy rain threaten flood-ruined Indonesia
-
Sri Lanka unveils cyclone aid plan as rains persist
-
Avatar 3 aims to become end-of-year blockbuster
-
Contenders plot path to 2026 World Cup glory after Trump steals show at draw
-
Greaves leads dramatic West Indies run chase in NZ Test nail-biter
-
World record-holders Walsh, Smith grab wins at US Open
-
Ukraine, US to meet for third day, agree 'real progress' depends on Russia
-
Double wicket strike as New Zealand eye victory over West Indies
-
Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease
-
Shinoda Dental Named Official Distributor of VHF Milling Machines, Strengthening Its Position in Digital Dentistry
-
Califf Surveying Becomes Leading Supplier of Leica Total Stations in Asia
-
New Memoir In Pursuit of Glory Exposes the High-Stakes Journey to from Laborer to Executive Leadership in a Male-Dominated Industry
-
Peace medal and YMCA: Trump steals the show at World Cup draw
-
NBA legend Jordan in court as NASCAR anti-trust case begins
-
How coaches reacted to 2026 World Cup draw
-
Glasgow down Sale as Stomers win at Bayonne in Champions Cup
-
Trump takes aim at Europe in new security strategy
-
Witness in South Africa justice-system crimes probe shot dead
-
Tuchel urges England not to get carried away plotting route to World Cup glory
-
Russian ambassador slams EU frozen assets plan for Ukraine
-
2026 World Cup draw is kind to favorites as Trump takes limelight
-
WHO chief upbeat on missing piece of pandemic treaty
-
US vaccine panel upends hepatitis B advice in latest Trump-era shift
-
Ancelotti says Brazil have 'difficult' World Cup group with Morocco
-
Kriecmayr wins weather-disrupted Beaver Creek super-G
-
Ghostwriters, polo shirts, and the fall of a landmark pesticide study
-
Mixed day for global stocks as market digest huge Netflix deal
NYSE - LSE
| RBGPF | 0% | 78.35 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| SCS | -0.56% | 16.14 | $ | |
| JRI | 0.29% | 13.79 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| BP | -3.91% | 35.83 | $ |
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and plans for first patient in first quarter of 2026. In parallel, CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.
More information on CASI is available at www.casipharmaceuticals.com.
INVESTOR CONTACT:
Ingrid Choong, PhD
650-619-6115
[email protected]
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
E.Rodriguez--AT
